Key
Points
- Previous evidence from placebo-controlled trials
demonstrated that montelukast is an effective preventer
medication in children with persistent asthma.
- Newer comparative studies suggest that the main
roles for montelukast are as an alternative to low-dose
inhaled corticosteroids (ICS) or cromones in children
with mild persistent asthma or frequent intermittent
asthma.
- Emerging additional roles for montelukast include
protection against viral-induced wheeze in children with
intermittent asthma, when given either as continual
therapy or short courses in response to the onset of
respiratory tract infections.
- There is accumulating evidence to support the use of montelukast to protect against exercise-induced bronchoconstriction in children.
